This service is designed to give you the identifications and quantifications of N-glycosylated peoteins/peptides in your complex biological samples. Glycosylated proteins/peptides will be enriched using hydrazide and then subject to downstream proteome identification or quantification through Mass Spectrometry Analysis. Your samples (several test groups and a control group) will be digested with Trypsin, and peptides will be enriched using hydrazide chemical, and treated by PNGase-F, followed by chemical labeling by either iTRAQ or TMT labeling method if a quantitative analysis is desired. Enriched (with or without labeling) peptideswill be cleaned using SCX HPLC and a bRPLC fraction to further generate the 2nd dimansion of separation which has been proved to significantly increase the coverage and depth of the Mass Spectrometry Analysis.

Data analysis, including data validation, visualization and quantification, are performed with commercial softwares and Complete Omics’ unique R packages and scripts. Report will be sent to you in Excel format as well as a summary in PDF format. We will also provide you any details you need for your papers’ MATERIALS AND METHODS section. We will make sure you understand your result and help you with your paper writing with free follow-up services.

Sample types we accept:

1, 2D gel spots, SDS-PAGE bands

2, Cell Lysates and Tissue Lysates

3, Biofluids, such as plasma*, serum*, saliva, tear, etc.

*We provide High Abundance Protein Depletion Service to significantly (100-500 folds) increase the depth of your biofluid proteomics analysis by removing top abundant proteins from your samples. Read more for details​.

4, FFPE slide/ FFPE extract

5, Customized sample types (please contact us to discuss)

Collaboration with Columbia University

Mar 30, 2022 | BALTIMORE –  Complete Omics’ Clinical Proteomics team announced a collaboration with Professor Kam W. Leong, Samuel Y. Sheng professor of Biomedical Engineering, and his team from…

Read more

Collaboration with Tel Aviv University

Mar 20, 2022 | BALTIMORE –  Complete Omics’ Clinical Proteomics team announced a collaboration with Professor Miguel Weil from Department of Cell Research and Immunology at the Tel Aviv University…

Read more

Detecting and Absolutely Quantifying Patient-specific Neoantigens from Limited Input of Biopsy Sample — An Integrated Pipeline for Neoantigen-targeted Cancer Treatments

Neoantigens derived from HERVs represent a new group of cancer therapeutic targets. In a collaborating project, Complete Omics identified and quantified HERVs derived neoantigens and provided solid evidence for developing…

Read more

Some of our impacts